BioSpace News Archive

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the results from its Phase 3 study of IV tramadol in patients undergoing bunionectomy have been published in the peer-reviewed journal, Pain and Therapy. The objective of this Phase 3 study was to compare the analgesic benefit and tolerability of two doses of IV tramadol (50 mg and 25 m

Afya Limited, or Afya announced the acquisition of 100% of the total share capital of PEBMED, through its wholly-owned subsidiary Afya Participações S.A.

Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 ( 18 F) in Biochemically Recurrent Prostate Cancer − Patient enrollment now underway in Phase 3 SPOTLIGHT as well as LIGHTHOUSE clinical trials in prostate cancer −

Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA ® Published in The Lancet Child & Adolescent Health -- Peanut-Allergic Patients Treated with PALFORZIA Showed Desensitization to Peanut Protein with a Predictable Safety Profile at Nine Months – --Clinically Meaningful Improvements in Food Allergy Quality of Life Were Reported in all Age Groups -- BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc.

With thorough precautions to minimize risk of COVID-19, patients can expect safe and personalized care.